Indian pharmaceutical stocks fell after US President Trump announced a phased tariff roadmap for imported generic medicines, highlighting concerns about the sector’s reliance on the US market. The plan provides a two-year tariff-free window, followed by 100% tariffs from August 2028 and 200% from August 2029, aimed at prompting manufacturers to establish US-based plants. Major names including Sun Pharma, Cipla, Dr Reddy’s, Lupin, Aurobindo Pharma, and Zydus Lifesciences traded lower, with the Nifty Pharma index and broader benchmarks slipping in early trading. Markets reflected weaker sentiment, with Sensex/Nifty down and stock moves ranging roughly 1% to 3%. The US remains India’s largest pharma export market, making the tariff plan a key risk to export volumes even as FY26 pharma exports to the US had shown some revival. Analysts and investors weighed localization against dependence on American demand, contributing to volatility in the Indian pharma pack.